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Cost comparison of asthma treatments in
12-week study: caution about matching
and short observational follow-up
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Abstract
In the absence of randomisation, observational studies must take extra care to create treatment groups that are
comparable in terms of key characteristics. Various matching methods exist which can create sound comparisons,
minimising confounding where possible. A recent observational study by Dal Negro et al. carried out a cost analysis
comparing two asthma medications. They report strong conclusions which favour one treatment over the other,
however they include little discussion on the limitations of their study. The purpose of this letter is to comment on
the weaknesses of the study design, including the level of matching used, and to urge readers to consider these issues
alongside the interpretation of results.
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Dear editors,
Multidisciplinary Respiratory Medicine recently published
the following study about asthma treatments: “Flutica-
sone furoate/Vilanterol 92/22 μg once-a-day vs Beclo-
methasone dipropionate/ Formoterol 100/6 μg b.i.d.: a
12-week cost analysis in mild-to-moderate asthma”, by
Dal Negro et al. We are moved to comment on this re-
search as there are several issues that we believe should
be brought to the attention of your readers to allow for
a more balanced interpretation of its results.
The first issue is that there is potentially serious con-
founding of the results due to poor study design. In an
observational study where no randomisation is carried
out, the authors are right to have applied propensity-
score matching, and have matched patients using age,
sex, FEV1 and co-morbidities. However, in a study where
asthma outcomes are being compared, it is vital that
asthma severity and treatment history are used as
matching criteria. FEV1 alone is not sufficient. In this
study scenario, it is absolutely key to know how these
patients have been treated in the baseline period. We
know that they were on a combination of long-acting
beta agonist and inhaled corticosteroids (LABA/ICS) for
at least 12 weeks during follow-up, but the authors do
not make clear when they were stepped-up to this ther-
apy. The potential for confounding is clear, as the out-
comes of a patient whose step-up was only recently
initiated may be different to those of a patient who has
had a longer period of treatment stability. It is also key
to know the event history (including exacerbations and
hospitalisations) of the study sample. These factors are
strongly predictive of future exacerbations [1] and the
results of a study which fails to account for these may
not be reliable. The reliability is questioned further due
to the small sample size of the study (only 40 patients in
each group), in which an imbalance between treatment
groups could be more problematic. The follow-up period
of 12 weeks is far too short to assess asthma outcomes;
longer-term observation periods (at least 6–12 months)
are needed to take into account variability in outcome
(especially given that asthma is a chronic disease) and
confounders such as seasonal variability. The authors ac-
knowledge this limitation, but mainly in order to present
it as the sole reason for a lack of significance in the dif-
ference between hospitalisation costs.
The second issue concerns the relevance and interpret-
ation of the results of the cost analysis. The authors car-
ried out a cost-consequence analysis, where disaggregated
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changes in clinical and cost outcomes are estimated.
Reporting results in a disaggregated way shifts the burden
of interpretation on to the consumer of the research or
clinical decision-maker [2]. What would be more useful is
to present the change in costs relative to change in conse-
quences, i.e. cost-effectiveness analysis. As for the results,
the mean reductions in costs for GP visits, specialist visits,
and hospitalisations are small and, whilst statistically sig-
nificant for GP and specialist visits, show very small shifts
in costs. For example, as reported by the authors, the cost
of an asthma-related hospitalisation with a comorbid dis-
ease was 2537 Euros and 1832 Euros without a comorbid
disease. The change in cost of hospitalisation (173 Euros)
between the groups was not statistically significant and it
could hardly be considered a meaningful change for health
care providers, as it accounts for roughly 7–9 % of the cost
of one hospitalisation. Similarly, costs for GP and special-
ist visits may have been statistically significant, but lack
meaningful changes in costs that would result in more
efficient or affordable use of one treatment over an-
other in this analysis. Based on these results, it is mis-
leading to claim in the conclusions that fluticasone
fuorate/vilanterol “showed clear potential for enhanced
clinical outcomes and reduced costs”. A more likely
conclusion would carefully claim that no meaningful
changes in costs occurred at 12 weeks and that ex-
tended follow-up with larger sample sizes are needed
prior to making claims on cost reductions.
There are some items in the paper that deserved fur-
ther discussion from Dal Negro et al. The first is the
relevance of their dose comparison. Although dose
choices are largely at the discretion of clinicians, based
on the Summary of Product Characteristics (SPC) of
fluticasone fuorate/vilanterol and clinical trial data
comparing fluticasone fuorate and fluticasone propion-
ate, [3–5] the dose of beclomethasone dipropionate
equipotent to fluticasone fuorate should be higher than
the dose used in this study. It would be of interest to
hear the authors’ perspective on the usefulness of their
comparison. The second item is that the rate of ob-
served hospitalisations in this mild to moderate study
sample is high in comparison with the literature. In
other studies, hospitalisation rates have been up to ten
times less over the equivalent follow-up period, even in
patients with uncontrolled asthma [6, 7]. This deserves
discussion as it raises the question of the representa-
tiveness of this sample. Thirdly, the method of adher-
ence measurement is not made clear in the paper. If we
assume dose counters on the devices were utilised,
there is an issue of comparability as the Nexthaler’s ad-
herence monitor counts inhaled doses, whereas the
Ellipta counts loaded doses. It is a relevant matter to
clarify as the authors write that they have used adher-
ence data to compute the cost of medications.
Lastly, an important limitation of the study is that
emergency department visits were not included in the
cost analysis, though this event is considered one of the
core recommended cost outcomes for asthma [8].
The points discussed above should be carefully consid-
ered when interpreting the results of this paper. We
hope that they will assist readers in making a fairer as-
sessment of Dal Negro’s study.
Authors’ response
Roberto W. Dal Negro and Sergio Iannazzo
We read carefully the letter received, and concerning
some criticisms to the paper “Fluticasone furoate/
Vilanterol 92/22 μg once-a-day vs Beclomethasone dipro-
pionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost ana-
lysis in mild-to-moderate asthma”, recently published in
Multidisciplinary Respiratory Medicine (2016;11:20).
We are rather surprised by the unfair and unbalanced
description of our study. The Authors of the letter es-
sentially mention that we draw “strong conclusions
which favour one treatment over the other” based on a
poor study design. We do not really see the strong con-
clusions in our paper, when the final sentence in the
published abstract stands out literarily as: “Even if both
ICS/LABA combinations were checked over a limited
period of time, they seem characterized by a different
profile in terms of their effect on lung function and of
their economic impact on mild-to-moderate asthma.
The once-daily inhalation of combined Fluticasone
furoate/Vilanterol 92/22 μg showed the potential for
enhanced clinical outcomes and reduced costs when
compared to Beclomethasone dipropionate/Formoterol
100/6 μg b.i.d.” In other terms we report a trend, which is
in the numbers, but that has to be confirmed by a longer
observation.
Furthermore, we wish to pinpoint that the study is an
observational, retrospective study, and that data were
obtained from an institutional general database which is
collecting files of asthma patients managed in real-life.
In other words, as clearly perceived from the paper, the
study does not belong to the traditional pharmacological
trials where subjects have to be preliminarily random-
ized into different arms. Actually, this was the main
reason for the adoption of the propensity matching
score. The Authors of the letter believe that we cor-
rectly applied the method but left key information
unmanaged, leading to a poor design. Essentially, they
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mention asthma severity and treatment history (i.e. when
patients were stepped up to study therapies) as key char-
acteristics that should have been used as matching criteria.
We believe this criticism derives from a misunderstanding
of our study. Differently from the opinion of the Authors’
letter, we do not perceive any “serious confounding”, be-
cause it appears very clearly that not-severe asthma was
the unique target of the survey. Actually, the high mean
basal FEV1 value (>82 % pred.), together with the low clin-
ical impact already registered in basal conditions do repre-
sent clear real-life indices from this point of view,
independently of previous patients’ therapeutic strategies.
Moreover, all automatically selected patients were
equally stepped-up exactly at their recruitment date
(such as 12 weeks ± 1 week before the end of the sur-
vey): previously, they were regularly treated and were in
consolidated stable conditions before their step-up date.
They also were well matched at the step-up date and abso-
lutely undistinguishable, both in terms of their lung func-
tion and of clinical impact. To underline that basal data
were obviously referred to the period immediately preced-
ing the start of the survey, and then what the Authors of
the letter were requiring and are worried of was already
reported in the paper (Table two, column A for both the
patients’ samples).
As concerning the duration of the survey, we only
wish to recall that, differently than in COPD, several
clinical trials carried out in asthma with the aim to
check and compare the effects of different drugs (vs pla-
cebo or not) had, and still have, a 12-week duration, and
that also international guidelines were affected by some
papers of this duration.
As concerning the extent of the clinical impact re-
ported at the step-up, we can only comment that it
should be unbelievable if the original exacerbation and
the hospitalization rates would have been higher in not-
severe asthma patients, already treated with other ther-
apies, as the patients of the study were.
Consequently, the achieved economic outcomes may
appear not impressive at glance. Nevertheless, the signifi-
cant difference registered in n. visits between the treat-
ments should not be neglected because occurring over a
12-week period only, and this particular piece of evidence
was still missing in literature, to our knowledge, when
comparing these two drugs. Obviously, nobody would
have expected highly dramatic changes in hospital admis-
sion and n. exacerbation rates in two sample of patients of
this severity, who were stepped up for three months only.
If occurring, it would have been regarded as a biased out-
come, in our opinion.
The only simple message from the present paper is
that some significant and unexpected differences in clin-
ical outcomes are occurring when comparing the two
treatments, even if within only 12 weeks, and in two
small samples of subjects. The differences registered
(such as in lung function and in reduction of unsched-
uled GPs’ and specialists’ visits) are in fact reflecting two
interesting aspects of asthma governance which proved
in favour of Fluticasone furoate/Vilanterol 92/22 μg
once-a-day) rather than of Beclomethasone dipropio-
nate/Formoterol 100/6 μg b.i.d., stepped up for a same
period of time. Some suggestions for explaining this dif-
ference had been reported in the paper. Once again, this
small piece of evidence was not available yet.
The authors of the letter also complain about the rele-
vance of the results of a cost analysis, or better that our
cost-analysis left disaggregated changes in cost and clin-
ical outcomes for the decision-makers, instead of cook-
ing for them a full cost-effectiveness analysis. This seems
in contradiction with their other criticism of poor study
design. We all well know that the cost-effectiveness is
the most informative analysis among the health econom-
ics armamentarium, however we felt that the results of
our study were just preliminary and as a consequence
their use in a cost-effectiveness analysis would have been
inappropriate. This again should reassure the reader that
we are not drawing “strong conclusions” on our data.
Finally, just to reassure the Authors of the letter, we
wish to inform that the survey had been originally planned
for a 12-month duration, and that results reported in the
present, recently published paper only represent the very
first cluster of data. The overall results collected over one
year are in advanced calculation, and their submission has
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